Biohaven signs Regeneron supply deal to test BHV-1530 with Libtayo
BHVN•Combination program and rationale
The program aims to pair BHV-1530’s TopoIx payload with anti-PD-1 therapy, citing preclinical synergy and immunogenic cell-death activity.
Existing relationship between the companies
The deal expands an existing supply arrangement between the companies tied to Biohaven’s TROP2-directed ADC BHV-1510.
Biohaven enters clinical supply agreement with Regeneron
Biohaven entered a clinical supply agreement with Regeneron to test FGFR3-targeted ADC BHV-1530 with cemiplimab (Libtayo) in solid tumors.
The combination plan follows early Phase 1 monotherapy signals for BHV-1530, including tumor reductions in FGFR3-altered or wild-type overexpressing cancers.
